Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Ani Pharmaceuticals (ANIP) Interest & Investment Income (2016 - 2026)

Ani Pharmaceuticals' Interest & Investment Income history spans 16 years, with the latest figure at -$4.4 million for Q4 2025.

  • On a quarterly basis, Interest & Investment Income rose 26.67% to -$4.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$20.1 million, a 13.96% decrease, with the full-year FY2025 number at -$20.1 million, down 13.96% from a year prior.
  • Interest & Investment Income hit -$4.4 million in Q4 2025 for Ani Pharmaceuticals, up from -$4.7 million in the prior quarter.
  • Over the last five years, Interest & Investment Income for ANIP hit a ceiling of -$2.3 million in Q3 2024 and a floor of -$7.7 million in Q1 2023.
  • Historically, Interest & Investment Income has averaged -$5.2 million across 5 years, with a median of -$5.5 million in 2025.
  • Biggest five-year swings in Interest & Investment Income: crashed 190.91% in 2022 and later surged 63.57% in 2024.
  • Tracing ANIP's Interest & Investment Income over 5 years: stood at -$4.4 million in 2021, then plummeted by 69.05% to -$7.5 million in 2022, then rose by 23.45% to -$5.7 million in 2023, then decreased by 4.68% to -$6.0 million in 2024, then grew by 26.67% to -$4.4 million in 2025.
  • Business Quant data shows Interest & Investment Income for ANIP at -$4.4 million in Q4 2025, -$4.7 million in Q3 2025, and -$5.4 million in Q2 2025.